The Impact of MFN Pricing on the U.S. Biosimila...

By Rene Pretorius

May 23, 2025

Could a cost-cutting policy designed to rein in drug prices backfire on biosimilar competition? The Most Favored Nation
Biosimilars Price Competition: Impact on U.S. Pharmaceutical Pricing and Mark...
MFN Drug Pricing Targets: Lowering U.S. Drug Costs Through International Alig...
HTA Reform Analysis: Patterns and Global Trends in Health Technology Assessment
Drug Pricing Analysis: ICER’s Launch Price and Access Report Aims to En...
Trends in Anticancer Drug Pricing: Analyzing Medicare Launch Prices and Impac...
Evolving NICE Health Technology Evaluations: Enhancing Patient Perspectives a...
Canada Drug Agency Plan: Shaping the Future of Health Systems 2025-2030
Hepatitis C Investment Impact: Maximizing Health and Economic Returns in China
MR-107A-02: Revolutionizing Non-Opioid Pain Management with Viatris’ Breakthr...
Prevention Valuation: Fund Health, Not Just Savings
FDA AI Drug Approval
Implementing Health Technology Assessment in Oman